Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 128 participants.
Also called NCT03271879
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 128 participants
- Registry
-
NCT03271879
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT03271879. Randomized; double masking; primary purpose treatment. Start 2018-02-15 (anticipated); primary completion 2019-09-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Empagliflozin Versus Placebo on the Rate of Arrhythmic Events in Heart Failure Patients
- Acronym
- ERA-HF
- Condition
- Heart Failure
- Condition
- Diabetes Mellitus
- Condition
- Arrythmia
- Intervention (Drug)
- Empagliflozin at a dose of 10 mg/day
- Lead sponsor
- Rambam Health Care Campus
- Collaborator
- Boehringer Ingelheim
Record details
- Record id
cardio:ct-nct03271879- Content hash
327c6a7c38c931385a4a0a1440ae3e1c68121866dad53e1c0278abb60484e41c